Crane NXT, Co. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crane NXT, Co. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.37B | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $770.50M | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | $833.50M | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | $796.40M | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | $779.60M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $683.60M | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | $686.50M | Feb 28, 2022 |
| FY2021 | Jun 30, 2020 | $644.30M | Feb 28, 2022 |
| FY2021 | Mar 31, 2020 | $746.90M | Feb 28, 2022 |
| FY2019 | Dec 31, 2019 | $837.50M | Feb 25, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.39B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.34B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.35B | Feb 22, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $714.20M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $695.90M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $702.50M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $673.40M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $681.60M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $694.20M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $712.20M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $660.00M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $680.60M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $669.90M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $288.00M | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | $324.40M | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | $319.60M | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | $309.00M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $227.40M | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | $243.20M | Feb 28, 2022 |
| FY2021 | Jun 30, 2020 | $219.50M | Feb 28, 2022 |
| FY2021 | Mar 31, 2020 | $275.00M | Feb 28, 2022 |
| FY2019 | Dec 31, 2019 | $289.40M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $277.90M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $184.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $188.30M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $204.90M | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | $72.10M | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | $116.60M | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | $138.30M | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | $108.40M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $46.90M | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | $56.60M | Feb 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $268.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $286.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $301.30M | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | $87.10M | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | $138.20M | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | $136.90M | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | $140.10M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $53.90M | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | $75.90M | Feb 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $39.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $33.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $33.20M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $74.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $74.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $89.10M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $58.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $61.50M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $440.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $386.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $366.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $318.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $323.40M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $698.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $678.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $711.90M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $605.90M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $610.60M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $214.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $276.30M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $306.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $277.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $309.50M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $393.90M | Feb 23, 2021 |
| FY2020 | Dec 31, 2018 | $413.80M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $317.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $318.10M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $31.10M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $21.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $18.60M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $34.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $64.40M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $108.80M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $49.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $51.50M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.12B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.39B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.13B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.13B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.49B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $4.62B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $4.42B | Feb 23, 2021 |
| FY2020 | Dec 31, 2018 | $4.04B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $3.59B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $3.43B | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.86B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.32B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.17B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.35B | Feb 22, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $964.00M | Feb 20, 2025 |
| FY2024 | Dec 31, 2022 | $783.80M | Feb 20, 2025 |
| FY2024 | Dec 31, 2021 | $763.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $914.10M | Feb 22, 2024 |
| FY2020 | Dec 31, 2019 | $1.47B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.52B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.35B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.13B | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $956.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $841.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $836.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $860.60M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.61B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $1.30B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.40B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.21B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.15B | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $374.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $268.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $120.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.53B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.19B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.11B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.07B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.81B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.72B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $165.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $227.20M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $230.70M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $478.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $551.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $393.90M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $343.40M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $706.20M | Feb 25, 2020 |
| FY2019 | Dec 31, 2016 | $509.70M | Feb 25, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $540.60M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $640.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $545.10M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $842.40M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $842.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $842.00M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $949.20M | Feb 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | 2 | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 20, 2025 |
| FY2021 | Dec 31, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Jun 30, 2021 | 2 | Feb 28, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 57.20M | Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | 56.90M | Feb 22, 2024 |
| FY2022 | Dec 31, 2022 | 56.33M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 57.84M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 58.13M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 59.00M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 59.51M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 59.41M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 58.96M | Feb 27, 2018 |